What is LOPJLB’s current signal on EDIT?

LOPJLB’s latest quantitative signal on Editas Medicine, Inc. (EDIT) is BUY in a RECOVERY regime. Signals are updated daily.

What market regime is EDIT in?

Editas Medicine, Inc. (EDIT) is currently classified in the RECOVERY HMM market regime on LOPJLB.

Editas Medicine, Inc. (EDIT)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$2.75-5.17%Close

BUYRECOVERY · day 6

RANGE

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONEBEST

Key stats

Short interest · FINRA settlement 2026-09-30

Market cap: $269M
Beta: 2.00
P/E (TTM): -3.65

Short % float: 37.97%
Days to cover: 9.3
SI change: +23.9%

1W: -1.43%
1M: +1.85%

vs SPY 1W: -1.86%
vs SPY 1M: -0.21%

Industry peers

FMP comparable companies · ranked by market cap

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a…

Employees: 87
Headquarters: US
Founded: 2016
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 97.9M
Float: 99.8%

editasmedicine.com ↗

Key executives

Gilmore O'Neill — President, Chief Executive Officer & Director

Linda C. Burkly — Executive Vice President & Chief Scientific Officer

Amy Parison — Senior Vice President & Chief Financial Officer

SEC filings

EDGAR · CIK 16506640 · EDIT

Analyst consensus

Buy

Bullish1661.5%

Neutral830.8%

Bearish27.7%

L $4.00Avg $5.00H $6.00

Target$5.00+81.82%

Last$2.75

FAQ

What is LOPJLB’s current signal on EDIT?: LOPJLB’s latest quantitative signal on Editas Medicine, Inc. (EDIT) is BUY in a RECOVERY regime. Signals are updated daily.
What market regime is EDIT in?: Editas Medicine, Inc. (EDIT) is currently classified in the RECOVERY HMM market regime on LOPJLB.
What does Editas Medicine, Inc. (EDIT) do?: Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. T…

Key stats

Industry peers

Prediction markets

Company news

FAQ